GLP-1 manufacturer Biosimilar CDMO and Sterile injectable 506e Outsourcing Facility

 

Executive Capability Sheet: MayMag Biologics

Company Overview: MayMag Biologics (formerly operating as Zeptide Pharma and Tirzepatide Pharma) is a premier U.S.-based cGMP pharmaceutical and biosimilar manufacturer. Headquartered in Garland, Texas, MayMag Biologics operates strictly at an industrial 506(e) manufacturing scale to deliver commercial-grade supply chain redundancy for wholesale distributors, hospital Group Purchasing Organizations (GPOs), and institutional procurement networks.

1. Manufacturing Scope & Strategic Positioning

  • 506(e) Industrial Focus: Unlike 503B retail/clinical compounding pharmacies, MayMag Biologics focuses exclusively on industrial, high-volume production of generic drugs and biosimilar biologics on the FDA Drug Shortage list.

  • Commercial Scale Fill-Finish: High-throughput sterile fill-finish operations engineered to preserve batch stability, integrity, and shelf-life throughout large-scale national distribution.

  • In-House Device Integration: Direct contract manufacturing and integration of proprietary 510(k) auto-injector pens and delivery hardware.

2. Regulatory Compliance & Quality Assurance

  • FDA Status: FDA-Registered cGMP 506(e) Manufacturing Facility.

  • Inspection Record: Clean FDA Form 483 history and zero warning letters.

  • Quality Standards: Fully compliant with ISO 13485 (Medical Devices), cGMP, USP <797>, and USP <800> guidelines for sterile compounding and biomanufacturing.

  • Supply Continuity: Multi-year, dual-sourced auto-pen supply agreements to insulate wholesale channels from single-point device failures.

3. Core Product & CDMO Lines for Distributors

Product CategoryManufacturing Focus & Offerings
Insulin & BiosimilarsLarge-scale formulation and fill-finish of Insulin 70/30 auto-pens, Insulin Aspart premix/vials, Insulin Glargine, and multi-dose KwikPen-style devices.
GLP-1 & Metabolic BiologicsCommercial-grade sterile injectable semaglutide and tirzepatide formulations, customized GLP-1 peptides, and oral GLP-1 therapeutics.
Auto-Injectors & Emergency MedicineEpinephrine auto-injectors (EpiPen equivalents) and anti-inflammatory rheumatoid arthritis (RA) delivery systems.
Ophthalmics & InhalationHigh-purity sterile glaucoma treatments, nasal sprays, and inhalation therapeutics.
Bacteriostatic Water & DiluentsIndustrial-scale production of Bacteriostatic Water for Injection (BWFI) with 0.9% benzyl alcohol preservative for multi-dose applications.

4. Distributor Value Proposition

  • Margin Protection: Streamlined U.S. manufacturing efficiency yields competitive, predictable unit economics designed to protect distribution margins from price erosion.

  • Domestic Supply Security: 100% U.S.-based facility eliminates long lead times and international shipping vulnerabilities during national drug shortages.

  • Private Label & OEM Services: Full white-label and contract manufacturing (CMO/CDMO) options for private-label distributor portfolios.

Contact & Credentials Validation



Comments

Popular posts from this blog

FDA approved Biosimilar Injectable Biologics Contract Manufacturer in USA-MayMag Biologics

Mastering Parenteral Delivery: Technical Excellence in GLP-1 and Insulin Device CDMO Services

Scaling Parenteral Drug Delivery: Why Next-Gen Biologics Demand a Specialized Device CDMO